Exploring the Potential of Voice Biomarkers for Monitoring Depression Symptoms

The Promise of Voice Biomarkers in Depression Monitoring

In an innovative stride within mental health diagnostics, PST Medical Corporation, headquartered in Tokyo, has made waves with their recent presentation at the 3rd Japanese Outpatient Psychiatry Conference. The company, led by CEO Ryosuke Michisuga, collaborated with 10 facilities from the Kanagawa Prefectural Psychiatric and Neurological Clinic Association to unveil the findings of their research into voice biomarkers and depression symptoms.

The study analyzed multiple voice recordings from both patients exhibiting depressive symptoms and healthy individuals, totaling 99 cases and 291 datasets. The core aim was to investigate the relationship between vocal features and the severity and fluctuations of depressive symptoms. The results were promising: a correlation coefficient of 0.62 was observed between the severity scores estimated from voice data and the Hamilton Depression Rating Scale (HAM-D) scores. Additionally, the study demonstrated an impressive Area Under the Curve (AUC) value of 0.82 with an accuracy rate of 77% when differentiating between normal and mild or severe cases based on HAM-D classifications.

What’s more compelling is the finding that changes in voice characteristics among the same patients might reflect trends in their depression symptoms. The analysis suggested that approximately 37% of the variability in depressive symptom changes could be explained by these vocal indicators, factoring in the previous severity and frequency of visits to clinical settings (marginal R² = 0.37).

These findings open a new gateway in understanding and monitoring depression. Traditionally, psychiatric evaluations are often limited to the patients’ in-clinic assessments. However, since voice measurements can be conducted quickly and non-invasively, they present an opportunity for continuous monitoring in patients’ daily lives. By facilitating an objective assessment of symptom changes over time, voice biomarkers could transform how practitioners manage patient care between visits.

PST Medical not only leverages several patents related to voice features but is also actively working to develop medical device programs based on these research outcomes. The company is committed to the societal implementation of voice biomarker technologies, aiming to enhance the clinical management of depression.

About PST Medical Corporation

PST Medical was established in January 2024 and is located at the Nihonbashi Life Science Building, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo. Under the leadership of Ryosuke Michisuga, its core business focuses on developing and selling medical device programs that utilize voice biomarkers as well as conceptualizing and launching related services. To learn more about their innovative work, visit their official website at PST Medical.